Пошук консенсусу в мультимодальному лікуванні раку прямої кишки

Андрій Вікторович Свинаренко

Анотація


За наявності раку прямої кишки після виконання технічно можливих операцій спостерігається висока частота регіонарних рецидивів, а загальна п’ятирічна виживаність пацієнтів не перевищує 45-50 %, причому спроба підвищити радикальність розширенням обсягу втручання дозволили домогтися лише деякого зниження частоти місцевих рецидивів. Основною метою комбінації хіміотерапії і променевої терапії є збільшення локального контролю та ерадикація віддалених метастазів

Ключові слова


рак прямої кишки; хірургія; променева терапія; хіміотерапія

Повний текст:

PDF (Русский)

Посилання


O`Connell M.J., Martenson J.A., Wieand H.S. et al. Improving adjuvant therapy for rectal cancer by combined protracted infusion fluorouracil with radiation therapy after curative surgery // N. Engl. J. Med. – 1994. – Vol. 331. – P. 502–507.

Tepper J.E., O`Connell M.J., Niedzwiecki D. et al. Adjuvan therapy in rectal cancer: Anasis of stage, sex and local control – final report of intergroup 0114 // J.Clin.Oncol. – 2002. – Vol. 20. – P. 1744–1750.

Lee J–H, Je–Hwan Lee, Jin–Hee Ahn et al. Randomized Trial of Postoperative Adjuvant Therapy in Stage II and III Rectal Cancer to Define the Optimal Sequence of Chemotherapy and Radiotherapy: A Preliminary Report // J. Clin. Oncol. – 2002. – Vol. 20. – P. 1751–1758.

Wolmark N.,Wieand H.S., Hyams D.M. et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02 // J. Nat. Cancer Inst. – 2000. – Vol. 92. – P. 388–396.

Pazdur R., Douillard J.-Y., Skilling J.R. et al. Multicenter phase III of 5–fluouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer // Proc. Am. Soc. Clin. Oncol. – 1999. – Vol. 18. – P. 1009a.

Carmichael J., Popiela T., Radstone D. et al. Randomized comparative study of Orzel (oral Uracil/Tegafur (UFT) plus leucovorin (LV) versus parenteral 5-fluouracil (5-FU) plus LV in patients with metastatic colorectal cancer // Proc. Am. Soc. Clin. Oncol. – 1999. – Vol. 18. – P. 1015a.

Fernandez-Martos, Jorge Aparicio, Carles Bosch et al. Preoperative Uracil, Tegafur, and Concomitant Radiotherapy in Operable Rectal Cancer: A Phase II Multicenter Study With 3 Years’ Follow–Up // J. Clin. Oncol. – 2004. – Vol. 22. – P. 3016–3022.

Van Custem E., Twelves C., Cassidy J. et al. Oral capecitabine compared intravenous fluorouracil plus leucovorin patients with metastatic colorectal cancer: results of a large phase III study // J. Clin. Oncol. – 2004. – Vol. 19. – P. 4097–4106.

Twelves C., Wong A., Nowacki M. et al. Capecitabine as adjuvant therapy for stage III colon cancer // N. Engl. J. Med. – 2005. – Vol. 353. – P. 2696–2704.

Dunst J., Reese T., Sutter T. et al. Phase I trial evaluating the the concurrent combination of radiotherapy and capecitabine in rectal cancer // J. Clin. Oncol. – 2002. – Vol. 20. – P. 3983–3991.

De Paoli A., Chiara S., Luppi G. et al. A phase II study of capecitabine (CAP) and preoperative radiation therapy in resectable, locally advanced rectal cancer (LARC)//ASCO Annual Meetting Proceedings (Post–Meeting Edition) // J. Clin. Oncol. – 2004. – Vol. 22. – abstr.3540.

Kim J.C., Kim J.C., Cho M.J. et al. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer / Int. J. Radiat.Oncol.Biol.Phys. – 2002. – Vol. 54. – P. 403–408.

Souglakos J., Androulakis N., Mavroudis D. et al. Multicenter dose–finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer // Int. J .Radiat. Oncol. Biol. Phys. – 2003. – Vol. 56(5). – P. 1284–1287.

Bosset J.F., Magnin V., Maingon P. et al. Preoperative radiochemotherapy in rectal cancer: Long–term results of phase II trial // Int. J. Radiat. Oncol. Biol. Phys. – 2000. – Vol. 46. – P. 323–327.

Stryker S.J., Kiel K.D., Rademaker A. et al. Preoperative chemoradiation for stages II and III rectal carcinoma // Arch. Surg. – 1996. – Vol. 131. – P. 514–519.

De la Torre A., Ramos S., Valcarcel F.J. et al. Phase II study of radiochemotherapy with UFT and low–dose oral leucovorine in patients with unresectable rectal cancer // Int. J. Radiat. Oncol. Biol. Phys. – 1999. – Vol. 45. – P. 629–634.

Hoff P., Abbruzzese J.L., Medgyesy D. et al. A phase II study of Xeloda (capecitabine) in patients with metastatic colorectal cancer demonstrating progression on 5–FU therapy // Proc. Am. Soc. Clin.Oncol. – 2000. – Vol. 19. – P. 993a.

Gerard J.–P., Bonnetain F., Conroy T. et al. Preoperative (preop) radiotherapy (RT) ± 5 FU/folinic acid (FA) in T3–4 rectal cancers: results of the FFCD 9203 randomized trial // ASCO Meeting Abstracts. – 2005. – Vol. 23. – P. 3504.

Keam S.J., Dunn C.J. and Figgitt D.P. Oxaliplatin: in operable colorectal cancer // Drugs. – 2005. – Vol. 65(1). – P. 89–96.

Rхdel C., Sauer R. // In: Multimodal Concept of Cytotoxic Drugs and Radiation Therapy/Ed. Brown J.M., Mehta M.P., Nieder C. Springer Verlag Berlin Heidelberg, 2006. – P. 267–283.

de Gramont A., Figer A., Seymour M. et al. Leucovorin and fluorouracil with or without oxaliplatin as first–line treatment in advanced colorectal cancer // J. Clin. Oncol. – 2000. – Vol. 18. – P. 2938–2947.

Giacchetti S., Perpoint B., Zidani R. et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil– leucovorin as first–line treatment of metastatic colorectal cancer // J. Clin. Oncol. – 2000. – Vol. 18. – P. 136–147.

Andre T., Boni C., Mounedji–Boudiaf L. et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for coloncancer // N. Engl. J. Med. – 2004. – Vol. 350. – P. 2343–2351.

Gerard J.–P., Chapet O., Nemoz C. et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high–dose radiation and oxaliplatin–containing regimen: the Lyon R–04 phase II trial // J.Clin. Oncol. – 2003. – Vol. 21. – P. 119–1124.

Rхdel C., Grabenbauer G.G., Papadopoulos T. et al. Phase I/II trial of capecitabine, oxaliplatin and radiation for rectal cancer // J.Clin. Oncol. – 2003. – Vol. 21. – P. 3098–3104.

Cassidy J., Tabernero J., Twelves C. et al. XELOX (capecitabine plus oxaliplatin): active first–line therapy for patients with metastatic colorectal cancer // J. Clin. Oncol. – 2004. – Vol. 22. – P. 2084–2091.

Kohne C.H., van Cutsem E., Wils J.A. et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer : Results of EORTC study 40986 // Proc. Am. Soc. Clin. Oncol. – 2003. – Vol. 22. – P. 254.

Douillard J.Y., Cunningham D., Roth A.D. et al. Irinotecan combined with fluorouracil compared with fluorouracil alone for metastatic colorectal cancer: A multicenter randomized trial // Lancet. – 2000. – Vol. 355. – P. 1041–1047.

Mehta V.K., Cho C., Ford J.M. et al. Phase II tral of preoperative 3D conformal radiotherapy, protracted venous infusion fluorouracil and weekly CPT–11, followed by surgery for ultrasound–staged T3 rectal cancer // Int. J. Radiat. Oncol. Biol. Phys. – 2003. – Vol. 55. – P. 132 –137.

Roh M.S., Petrelli N., Wieand S. et al. Phase III randomised trial of preoperative versus postoperative multimodality therapy in Patients with carcinoma of the rectum (NSABP R–03) // Proc. Am. Soc. Clin.Oncol. – 2001. – abstr. 490.

Camma C., Giunta M., Fiorica F. et al. Preoperative radiotherapy for resectable rectal cancer;a meta-analysis // JAMA. – 2000. – Vol. 284. – P. 1008–1015.

Colorectal Cancer Collaborative GrouP. Adjuvant therapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials // Lancet. – 2000. – Vol. 358. – P. 1291–1304.

Janian N.A., Khoo V.S., Abbruzzese J. et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer // Int. J. Radiat. Oncol. Biol. Phys. – 1999. – Vol. 44. – P. 1027–1038.


Посилання

  • Поки немає зовнішніх посилань.